Project Grant R01DK144080
Award Date 8/15/26
Completion Date 4/30/31
Dollars Obligated $700K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $133,500 on May 5, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms of hemoglobin developmental switching as a therapeutic target for sickle cell disease and beta-thalassemia. The project, titled "Control of Hemoglobin Expression by the Chromatin Remodeler CHD7" (R03DK147724), will characterize...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $853,295 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to define bone marrow factors supporting neonatal hematopoiesis. The award funds investigation of how critical illness and sepsis in the neonatal period perturb bone marrow niche development and function, with focus on CXCL12-abundant reticular (CAR)...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $837,620 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to establish quantitative, non-invasive imaging biomarkers measuring autosomal recessive polycystic kidney disease (ARPKD) with congenital hepatic fibrosis (CHF) severity. The award funds development of ultrasound elastography, two- and three-dimensional...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $695,683 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop improved stem cell-derived beta cells for cellular therapeutics of diabetes. The project, titled "Making a Better Beta Cell for Cellular Therapeutics of Diabetes," focuses on engineering human pluripotent stem cell-derived beta cells capable...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $2,712,905 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop safe, effective, and scalable curative therapies for hemoglobinopathies including sickle cell disease, alpha-thalassemia, beta-thalassemia, and Fanconi anemia by targeting hematopoietic stem cells in vivo using antibody-directed, lipid nanoparticle delivery systems. The research strategy...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia Research Institute $1.868 million on June 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct integrative proteomics, metabolomics, and genomics analysis identifying mechanistic pathways of adverse outcomes in pediatric chronic kidney disease. The research leverages stored biosamples and existing data from over 1,100...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $318,816 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support a five-year mentored clinical scientist research career development award (K08 mechanism) focused on elucidating the role of effector CD8 T-cell and Kupffer cell interferon-gamma interactions in pediatric activated T-cell acute liver failure....
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia Research Institute $159,288 on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to elucidate the role of interleukin-22 in Hirschsprung associated enterocolitis pathogenesis. The award funds basic biomedical research investigating interleukin-22 (IL22) as a therapeutic target for Hirschsprung disease associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $889,998 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate a model for early identification and prevention of type 1 diabetes using polygenic risk score screening and CAR-T-regulatory cell therapy. The project combines genetic data and electronic health records from 4,000 pediatric...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $1.661 million to The Children's Hospital of Philadelphia on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of autophagy in intestinal epithelial regeneration following injury. The funded research examines how facultative intestinal stem cells (F-ISCs) acquire injury resistance and regenerative capacity through...